

Resource Summary Report

Generated by [kravitz2](#) on Aug 9, 2026

Sysmex Inostics

RRID:SCR_025629

Type: Tool

Proper Citation

Sysmex Inostics (RRID:SCR_025629)

Resource Information

URL: <https://sysmex-inostics.com/>

Proper Citation: Sysmex Inostics (RRID:SCR_025629)

Description: Biotechnology company in Baltimore, Maryland, specializing in liquid biopsy. Offers comprehensive NGS testing services for clinical trials, enhancing oncology drug development and patient outcomes.

Synonyms: Sysmex Inostics Inc.

Resource Type: commercial organization

Keywords: liquid biopsy, NGS testing services for clinical trials,

Resource Name: Sysmex Inostics

Resource ID: SCR_025629

Record Creation Time: 20240816T053258+0000

Record Last Update: 20260808T190722+0000

Ratings and Alerts

No rating or validation information has been found for Sysmex Inostics.

No alerts have been found for Sysmex Inostics.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Liang J, et al. (2026) Loss of luminal lineage drives resistance to next-generation ER?? antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. Nature communications, 17(1).

Dummer R, et al. (2025) Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(11), 2097.

Wesolowski R, et al. (2025) Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(19), 4040.